Isomorphic Labs Secures $5 Billion Series C as AI-Designed Drugs Near First Human Trials

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital to take its first AI-designed drug candidates into clinical trials. The raise follows a $2.1 billion Series B in May and comes as founder Demis Hassabis bets the company's drug-design engine can turn AlphaFold-era biology into real medicines.

Nov 18, 2026 - 21:26
 0  5
Isomorphic Labs Secures $5 Billion Series C as AI-Designed Drugs Near First Human Trials
Demis Hassabis, founder and chief executive of Isomorphic Labs, wearing blue-framed glasses and a black shirt, photographed indoors in front of blurred golden spherical lights.

Isomorphic Labs Secures $5 Billion Series C as AI-Designed Drugs Near First Human Trials

Isomorphic Labs has raised $5 billion in a Series C funding round, giving the AI drug-discovery company the firepower to take its first computationally designed drug candidates into human clinical trials. The London-based company, spun out of Google DeepMind in 2021, announced the round on Tuesday, November 17.

The round was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, and every existing backer returned, including Alphabet's venture arms GV and CapitalG, Thrive Capital, MGX, Temasek and the U.K. Sovereign AI Fund.

It is the second multibillion-dollar raise in six months for Isomorphic Labs. The company closed a $2.1 billion Series B in May, led by Thrive Capital. The new money will fund further development of its drug-design engine, expansion into more areas of medicine, and the infrastructure needed to move candidates from the computer into the clinic.

From protein predictions to real medicines

Isomorphic Labs builds an AI drug-design engine, known as IsoDDE, that uses a range of simulation models to explore chemistry and design new drugs, predicting their properties and refining them before scientists decide which candidates to make and test. The work builds on AlphaFold, DeepMind's protein-structure prediction system, which earned founder Demis Hassabis and former DeepMind director John Jumper the Nobel Prize in Chemistry.

The company says its programs have produced positive preclinical results in oncology and immunology, both in its own pipeline and in work with partners. It has struck deals with pharmaceutical giants Eli Lilly, Novartis and Johnson & Johnson.

Founder and chief executive Demis Hassabis said the round lets the company accelerate its work on foundational biology models and drive its first therapeutic programs toward clinical trials "to deliver tangible impact for patients."

A first fundraise under a new focus

The Series C is Isomorphic Labs' first fundraise since Hassabis stepped down as head of DeepMind to concentrate on drug discovery, moving into a chairman role at the AI lab. The shift underlines how central the drug-discovery bet has become to Alphabet's AI ambitions.

Hassabis said in January that he expected Isomorphic's first clinical trials to begin by the end of 2026. The Series C announcement gives no date for a first trial and names no clinical candidate, so the real test of the platform — whether AI-designed molecules work in people — is still ahead.

Valuation stays undisclosed

Isomorphic Labs did not disclose its new valuation. Bloomberg reported earlier in November that the company was looking to raise funding at a $50 billion valuation, a figure the company has not confirmed.

Whatever the valuation, the scale of the round puts Isomorphic Labs among the best-funded private biotech companies in the world — and raises the stakes for a field that has so far produced impressive predictions but no approved AI-designed drug.

Sources

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
Nahid Joy I’m Nahid Hasan Joy, a technology writer, web developer, and digital enthusiast with a strong interest in the ever-changing world of technology.